Loading...
WCLC congress 20172025-01-28T16:43:53+01:00

WCLC 2017 – Yokohama

Lecture Board: John Edwards, MB,ChB,PhD; Maximilian Hochmair, MD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from WCLC 2017

WCLC 2017 English

Full report (english)

WCLC 2017 Mandarin

Full report (mandarin)

WCLC 2017 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from WCLC 2017

David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

Paul A. Bunn discusses current and future treatment options in lung cancer.

Clinical trials conducted in Asia have contributed considerably to the development of targeted therapies, such as EGFR or ALK tyrosine kinase inhibitors, and immunotherapies, but also to the implementation of cytotoxic drugs. Particularly in lung cancer, Eastern Asia has evolved into a stronghold of cancer research over the previous years.

Fred R. Hirsch • MD • PhD, Dep. of Pneumology, Hopitaux Universitaires de Strasbourg
Go to Top